Clinical Research Focus. 57th Edition

Gene Therapy Meets Primary Endpoint in First Successful Pivotal XLRP Trial 

Beacon Therapeutics’ gene therapy laru-zova met the primary endpoint in the pivotal VISTA trial for X-linked retinitis pigmentosa, a rare inherited disease with no approved treatments. At 12 months, 31% of high-dose and 24.1% of low-dose patients achieved a ≥15-letter improvement in low-luminance visual acuity, versus none in the untreated group. Beacon plans to begin a rolling BLA submission later this year.  

Learn more 

Rare Disease Recruitment Is Getting Harder. Is Türkiye Being Overlooked? 

Rare disease trials increasingly compete for limited patient populations. In our latest article, Pelin Özdemir, Cromos Pharma’s Country Manager in Türkiye, explores why Türkiye may offer an important recruitment opportunity, from distinctive disease epidemiology and national screening programs to specialist referral networks and growing clinical research infrastructure. 

Learn more 

FDA Launches Expedited IND Pilot to Accelerate First-in-Human Trials 

The FDA has launched its Expedited IND Pilot, introducing rolling review of individual IND components during the pre-IND phase to help identify and resolve issues earlier. The program aims to reduce the risk of clinical holds and shorten timelines from drug development to first-in-human trials. Applications are open through October 30, 2026, with 8–10 sponsor–qualified research institution pairs expected to join the initial cohort.  

Learn more 

Alzheimer’s Clinical Trials in 2026: 5 Key Trends 

Alzheimer’s clinical research is shifting toward earlier intervention, biomarker-driven recruitment and more diverse therapeutic targets. With 158 drugs across 192 active trials, competition for increasingly specific patient populations is also growing. We look at five trends reshaping Alzheimer’s trials and what they mean for sponsors planning the next generation of studies.  

Learn more 

Brain Implant Enables Simultaneous Speech and Gestures in People With Paralysis 

An NIH-funded team has developed a brain-computer interface that can decode speech and upper-body gestures at the same time, allowing people with severe paralysis to control a personalized virtual avatar. Tested in three participants, the proof-of-concept marks a step toward BCIs that could restore more natural, expressive communication.  

Learn more 

Rejected Twice, Then Approved: Replimune’s FDA Reversal 

After two FDA rejections, Replimune’s Tudriqev (formerly RP1) ultimately secured accelerated approval for advanced melanoma. The case shows how regulatory decisions can evolve even when uncertainty remains, and highlights important lessons for sponsors around trial design, regulatory engagement, and the totality of clinical evidence.  

Learn more 

Gene-Edited Pig Kidney Sets New Transplant Record 

A gene-edited pig kidney kept a patient with end-stage kidney disease off dialysis for a record 271 days. The patient later successfully received a human donor kidney, with no evidence that the earlier xenotransplant compromised the subsequent transplant. The case provides new evidence that genetically modified pig organs could potentially serve as a bridge for patients awaiting human donor organs. 

Learn more 

China Built an AI-Agent Eye Clinic. Here Is What Happened in the Real World 

Researchers at Tsinghua University have deployed AI-TEC, an eye clinic where multiple AI agents support patients across the care journey, from triage and diagnosis to patient education and follow-up. Its real-world implementation revealed a critical lesson: strong AI performance alone is not enough. Data quality, physician adoption and workflow integration can ultimately determinewhether AI delivers meaningful clinical value. 

Learn more 

The Obesity Drug Race: Who Can Challenge Lilly and Novo? 

The obesity drug market is entering a new phase. As Lilly and Novo continue to raise the efficacy bar, competitors are pursuing oral drugs, next-generation incretins, amylin-based therapies and longer dosing intervals. The next wave of competition may be defined not only by greater weight loss, but also by tolerability, convenience, patient persistence and benefits in specific comorbidities. 

Learn more